Statements (37)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
antineoplastic agent anthracenedione |
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvedBy |
gptkb:European_Union
|
| gptkbp:ATCCode |
L01DB18
|
| gptkbp:brand |
gptkb:Pixuvri
|
| gptkbp:CASNumber |
144510-96-3
|
| gptkbp:compatibleWith |
gptkb:United_States
|
| gptkbp:developedBy |
Cell Therapeutics, Inc.
|
| gptkbp:drugClass |
antitumor antibiotics
anthracenediones |
| gptkbp:hasMolecularFormula |
C14H15N5O2
|
| gptkbp:hasSMILES |
CC(C)NCCN1C2=CC(=O)C3=C(C2=O)C=C(C=C3N(CCN(C)C)C)C1=O
|
| https://www.w3.org/2000/01/rdf-schema#label |
Pixantrone
|
| gptkbp:IUPACName |
1,4-dihydroxy-5,8-bis[2-(2-methylethylamino)ethylamino]anthracene-9,10-dione
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
DNA intercalation
topoisomerase II inhibition |
| gptkbp:PubChem_CID |
6918493
CHEMBL1201832 5293772 |
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
nausea
vomiting alopecia infections neutropenia cardiotoxicity myelosuppression |
| gptkbp:synonym |
gptkb:Pixuvri
BBR 2778 BBR-2778 |
| gptkbp:UNII |
6J8OL0BA3D
|
| gptkbp:usedFor |
leukemia
|
| gptkbp:bfsParent |
gptkb:Servier_Pharmaceuticals
|
| gptkbp:bfsLayer |
7
|